Drug
trenibotulinumtoxinE clinical trials
Also written AGN-151586.
Keep track of what changes. Save the trenibotulinumtoxinE studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2022 | 4 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses trenibotulinumtoxinE is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar LinesRecruitingPhase 1AbbVieNCT07756580Written as AGN-151586
- A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult ParticipantsActive, not recruitingPhase 2AbbVieNCT07730554Written as AGN-151586
- A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar LinesCompletedPhase 3AbbVieNCT05248893Written as AGN-151586
- A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar LinesCompletedPhase 1AbbVieNCT05496335Written as AGN-151586
- Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar LinesCompletedPhase 1AbbVieNCT06151561Written as AGN-151586
- A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar LinesCompletedPhase 3AbbVieNCT06308198Written as AGN-151586
- A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar LinesCompletedPhase 3AbbVieNCT05248880Written as AGN-151586
- A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)CompletedPhase 1AbbVieNCT06834789Written as AGN-151586
- A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar LinesCompletedPhase 3AbbVieNCT05248867Written as AGN-151586
- AGN-151586 Dose-Ranging Study for Treatment of Glabellar LinesCompletedPhase 2AllerganNCT04096326Written as AGN-151586